|
Synonyms: ATYR-1923 | ATYR1923 | KRP-R120
Compound class:
Peptide
Comment: Efzofitimod (ATYR1923) is a Fc fusion protein [1]. The C-terminal 59 amino acids corresponds to the active N-terminal domain of histidyl-tRNA synthetase (HARS), an extracellular non-catalytic isoform that is upregulated by inflammatory cytokine stimulation in the lung. The IgG1 Fc domain extends the peptide's circulating half-life. The HARS domain binds selectively to the cell surface receptor neuropilin 2 (NRP2; O60462, which is an immunomodulatory protein and molecular target for inflammatory diseases [5]. In the airways, NRP2 plays an important role in activation of myeloid cells and their recruitment to inflammatory sites [3]. Efzofitimod was developed as a clinical candidate immunotherpy with potential for immune-mediated fibrotic lung conditions.
|
| No information available. |
Summary of Clinical Use  |
| Efzofitimod (ATYR1923) is a clinical candidate. Based on evidence that the efzofitimod target NRP2 was upregulated by inflammatory cytokines in SARS-CoV-2 infections [4], a clinical study was designed to evaluate efzofitimod in patients with severe COVID-19-related pneumonia. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05415137 | Efficacy and Safety of Intravenous Efzofitimod in Patients With Pulmonary Sarcoidosis | Phase 3 Interventional | aTyr Pharma, Inc. | ||
| NCT04412668 | Study to Evaluate the Safety and Efficacy of ATYR1923 (Efzofitimod) In Participants With Severe Pneumonia Related to COVID-19 | Phase 2 Interventional | aTyr Pharma, Inc. | ||
| NCT03824392 | Study of Intravenous ATYR1923 (Efzofitimod) for Pulmonary Sarcoidosis | Phase 1/Phase 2 Interventional | aTyr Pharma, Inc. | 2 | |
